Indivior Presentations About Sublocade For The October 31, 2017, Joint Meeting Of The FDA Psychopharmacologic Drugs Advisory Committee & The Drug Safety & Risk Management Advisory Committee

On October 31, 2017, Indivior gave this presentation to an advisory committee of the U.S. Food and Drug Administration (FDA) to seek approval for RBP-6000 (extended-release buprenorphine), to be sold under the trade name "Sublocade.". The medication is designed as a monthly injection for the treatment adults with opioid use disorder.

. . .